Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →Coforge Ltd — Q3 FY25
Coforge delivered an exceptionally strong Q3 FY25 with sequential CC revenue growth of 8.4% and YoY CC growth of 40.3%, driven by broad-based strength across geographies, verticals, and service lines.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Coforge delivered an exceptionally strong Q3 FY25 with sequential CC revenue growth of 8.4% and YoY CC growth of 40.3%, driven by broad-based strength across geographies, verticals, and service lines. Adjusted EBITDA margin expanded 122 bps sequentially to 17.8%, despite furlough headwinds. The company signed four large deals, contributing to a 12-month order book of $1.37 billion, up 40.1% YoY. Management expressed confidence in sustained robust growth, citing a strong deal pipeline and improving demand environment. Key risks include potential macroeconomic headwinds and integration challenges from the Cigniti merger.
कोफोर्ज ने तीसरी तिमाही में शानदार प्रदर्शन किया। कंपनी की आय पिछली तिमाही से 8.4% और पिछले साल की समान तिमाही से 40.3% बढ़ी। यह वृद्धि दुनिया भर के सभी क्षेत्रों और सेवाओं में हुई। कंपनी का मुनाफा (EBITDA) 17.8% तक पहुंच गया, जो पिछली तिमाही से 1.22% अधिक है। कोफोर्ज ने चार बड़े सौदे किए, जिससे 12 महीने का ऑर्डर बुक 1.37 अरब डॉलर हो गया - पिछले साल से 40.1% ज्यादा। कंपनी को भविष्य में भी अच्छी वृद्धि की उम्मीद है। हालांकि, अर्थव्यवस्था में कमजोरी और सिग्निटी के साथ विलय की चुनौतियां जोखिम हो सकती हैं।
Promises0 met · 2 missedRisks3 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
3 risks
Risk Intelligence
Potential macroeconomic headwinds affecting client budgets
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Sequential CC Revenue Growth
8.4%
+8.4% QoQ
Exceptional growth in a seasonally weak quarter, driven by all geos and verticals.
12-Month Signed Order Book
$1.37B
+40.1% YoY
Order book growth reflects strong deal wins and robust pipeline.
Large Deals Signed
4
Flat QoQ
Second consecutive quarter with over $500M order intake; deals span AWM, ASEAN, airline, and insurance.
Cigniti EBITDA Margin
17.3%
+600 bps vs. pre-acquisition
Cigniti margins improved from ~11% three quarters ago, exceeding expectations.
What Changed vs Last Quarter
NEW
EBIT margin expansion to ~13.5% by Q3 FY26
CFO Saurabh Goel guided that EBIT margin should expand from 11.8% currently to roughly 13.5% by Q3 next year, driven by ESOP cost tailwinds and operational improvements.
NEW
ESOP cost to decline to ~100 bps of revenue by Q3 FY26
ESOP cost is expected to reduce from current ~210 bps to ~150 bps by Q1 FY26 and further to ~100 bps by Q3 FY26, providing margin tailwinds.
NEW
Sustained robust growth expected in coming year
CEO Sudhir Singh expressed confidence in continued robust and sustained growth, citing strong order book, pipeline, and broad-based demand.
DROPPED
Cigniti standalone EBITDA margin target raised to 18%+ by Q4 FY25
Management now expects Cigniti's EBITDA margin to exceed 18% by the end of the fiscal year, up from the earlier target of 16.5%.
DROPPED
Medium-term revenue target of $2B with concurrent margin expansion
Management reiterated its medium-term guidance of reaching $2B in revenue while delivering material EBITDA margin expansion.
DROPPED
ESOP cost headwind of ~120bps incremental in Q3 and Q4
CFO guided that incremental ESOP cost will be ~120bps per quarter for the next two quarters, with total ESOP cost of ~180-200bps.
NEW RISK
Potential macroeconomic headwinds affecting client budgets
Analyst raised concerns about demand environment during budget season; management acknowledged gradual improvement but risks remain if macro conditions worsen.
NEW RISK
Integration and merger-related expenses
Cigniti merger involves ongoing integration costs; CFO noted expenses were $1.9M in Q3 and expected to decline but could persist.
NEW RISK
Cross-sell synergies from Cigniti may take time
Management indicated cross-sell pipeline takes ~3 quarters to materialize; only limited cross-sell in current large deal.
RISK GONE
ESOP cost headwind impacting margins
Incremental ESOP cost of ~120bps per quarter in H2 FY25 will pressure reported EBITDA margins.
RISK GONE
Furloughs in Q3 could impact sequential growth
Management expects normal furloughs in Q3, which could temper the strong sequential growth trajectory.
RISK GONE
GCC deal revenue durability risk
Some GCC deals have a build-operate-transfer structure, leading to potential revenue cliff after the initial mandate period.
RISK GONE
Integration and past liability risks from Cigniti
While management expects no further past liabilities, integration expenses may persist for a couple of quarters.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q3 FY24
Management reaffirms guidance of 50 bps improvement in adjusted EBITDA margin for the full fiscal year, with H1 margins expected to be 50 bps higher than H1 FY24.
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Management expects to deliver within the annual guidance range of 13%-16% organic constant currency revenue growth, likely near the lower end.
Mentioned in Q1 FY25, Q2 FY25, Q4 FY24
While management expects no further past liabilities, integration expenses may persist for a couple of quarters.
Mentioned in Q1 FY25, Q4 FY24
Analyst raised concern that GenAI could deflate volumes in testing; management downplayed risk but acknowledged functional testing may be impacted.
Mentioned in Q1 FY24, Q4 FY24
New large deals, especially in new accounts, come with lower initial margins, which could pressure overall profitability.
Fast read
Guidance and risk preview
CFO Saurabh Goel guided that EBIT margin should expand from 11.8% currently to roughly 13.5% by Q3 next year, driven by ESOP cost tailwinds and ope...
Analyst raised concerns about demand environment during budget season; management acknowledged gradual improvement but risks remain if macro condit...
View Risks →